PCI Biotech: Unveiling The 2025 Half-Year Interim Report
PCI Biotech has halted development of its photochemical lysis platform for viral vector manufacturing and signaled a going-concern risk...
No videos found.
Mesoblast’s Remarkable Year: FDA Approves Ryoncil® Launch
Mesoblast reported its fiscal 2025 results and, more importantly for the market, its first quarter of commercial sales for...
Rakovina Therapeutics Announces New Q2 Financial Results Update
Rakovina Therapeutics reported a Q2 2025 net loss of $2.9 million. It ended the quarter with $1.88 million in...
Minovia Gets $350K Grant for Blood Biomarker Research
Minovia Therapeutics has secured a $350,000 grant from the philanthropic group Countdown for a Cure to advance blood-based mitochondrial...
YD Bio Announces Successful NASDAQ Listing and Combination
YD Bio Limited has completed its business combination with Breeze Holdings Acquisition Corp. and will begin trading on the...
Cytomed’s Acquisition Unlocks Auto-Immune Disease Focus
Cytomed Therapeutics has expanded clinical-scale natural killer cells from cord blood units cryopreserved for more than a decade and...
Can-Fite Reports H1 2025 Financial, Clinical Results
Can-Fite Biopharma reported mid-year 2025 results alongside several clinical updates: its Phase 2a study of namodenoson in advanced pancreatic...
Nurexone Biologic Inc. Reveals Q2 2025 Financial Results
Nurexone Biologic reported its second-quarter 2025 results and advanced a series of steps toward first-in-human testing of ExoPTEN, its...
FDA Approves Idorsia’s Tryvio for Systemic Hypertension
Idorsia is sharpening the commercial and scientific positioning of Tryvio (aprocitentan), releasing an on-demand webcast that frames the first-in-class...
MannKind to Acquire scPharma, Accelerating Growth
MannKind Corporation’s acquisition of scPharmaceuticals for up to $360 million, including milestone-based contingent value rights (CVRs), marks a decisive...